SynthesisJournal of neuro-oncology2026
Leveraging biometric data for meaningful outcome assessments in the care of patients with brain tumors: a systematic review.
Synthesis in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeWearable technologies are increasingly utilized in oncology to provide continuous, noninvasive monitoring of physiological and functional metrics. While feasibility has been demonstrated in several cancer populations, their role in neuro-oncology, particularly among brain tumor patients, remains underexplored.
methodsWe conducted a comprehensive literature search of PubMed, Scopus, and IEEE Xplore from 2009 to 2024. Extracted data included device characteristics, feasibility and adherence, physiologic monitoring, functional status, treatment monitoring, quality of life, and palliative care applications.
resultsInitial search yielded 1,312 articles, out of which 28 studies were included. Wearable devices demonstrated high feasibility for tracking physical activity and sleep across breast, lung, gastrointestinal and head and neck cancers, with adherence ranging from 31% to over 90%. Actigraphy-derived sleep and circadian metrics were correlated with chemotherapy toxicity, fatigue and risk of hospitalization. Objective activity measures often revealed discordance with clinician-rated performance scores. Biometric tracking was also found to be feasible in assessing toxicity of chemotherapy and for measuring impact of educational programs focused on increasing physical activity in cancer patients. In brain tumor care, where neurologic function, cognition and fatigue are critical yet variably assessed, wearable technologies may provide early warning signs of decline or complications such as steroid effects or seizure onset.
conclusionWearable technologies offer a scalable, patient-centered means to enhance monitoring in oncology. Despite these advances, few studies address neuro-oncology specifically. The current evidence highlights potential applications for brain tumor patients.
Indexed as
Identifiers
41870686What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.